Wall Street ends higher with help from tech, energy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
bluebird bio (BLUE) Prices 3.24M Share Common Offering at $185/Sh
December 13, 2017 5:44 AM ESTbluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of 3,243,244 shares of its common stock at a public offering price of $185 per share,... More
UPDATE: Celgene (CELG) PT Raised to $110 at Wells Fargo on 'bb2121 and Next-Gen CelMods' Updates at ASH Meetings
December 12, 2017 8:11 AM EST(Updated - December 12, 2017 8:12 AM EST)
Wells Fargo raised its price target on Celgene (NASDAQ: CELG) to $110.00 (from $101.00) while maintaining a Market Perform rating, following meetings at the American Society of Hematology.
Analyst Birchenough notes a positive outlook on the shares, following the... More
bluebird bio (BLUE) PT Raised to $225 at Wedbush
December 11, 2017 1:29 PM ESTWedbush raised its price target on bluebird bio (NASDAQ: BLUE) to $225.00 (from $174.00) while maintaining an Outperform rating after the company reported positive data in all three reported clinical programs.
"Early Group C data for sickle cell disease at 30 days were encouraging, and five... More
bluebird bio (BLUE) PT Raised to $223 at SunTrust Robinson Humphrey
December 11, 2017 8:53 AM ESTSunTrust Robinson Humphrey analyst Edward Nash raised his price target on bluebird bio (NASDAQ: BLUE) to $223.00 (from $163.00) while maintaining a Buy rating.
Nash cited the "robust durability data across all programs" presented at ASH.
"We believe the new process... More
